Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($1.01) by $0.63, FiscalAI reports.
Cartesian Therapeutics Trading Up 11.1%
Shares of RNAC stock traded up $0.75 during trading on Friday, hitting $7.53. The company had a trading volume of 121,614 shares, compared to its average volume of 129,075. Cartesian Therapeutics has a one year low of $5.60 and a one year high of $11.00. The stock’s 50-day moving average price is $7.40 and its 200 day moving average price is $7.64.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on RNAC. Wedbush restated an “outperform” rating and set a $38.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, August 18th. Wall Street Zen upgraded shares of Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Cartesian Therapeutics in a research report on Wednesday, September 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $40.00 target price on shares of Cartesian Therapeutics in a research report on Tuesday, September 29th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $32.60.
View Our Latest Stock Report on RNAC
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc (NASDAQ: RNAC) is a clinical-stage biotechnology company focused on developing mRNA cell therapies for autoimmune diseases. The company’s platform is designed to program a patient’s own immune cells with messenger RNA, enabling the development of cell therapies that are intended to provide targeted treatment without permanent genetic modification.
Cartesian’s lead product candidate is Descartes-08, an autologous CAR T-cell therapy that targets B-cell maturation antigen (BCMA).
Further Reading
- Five stocks we like better than Cartesian Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
